Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | peptidyl-prolyl cis-trans isomerase/rotamase, putative | 0.0097 | 0.9639 | 1 |
Trypanosoma cruzi | peptidyl-prolyl cis-trans isomerase | 0.0097 | 0.9639 | 1 |
Trichomonas vaginalis | pantothenate kinase, putative | 0.0082 | 0.7261 | 0.6597 |
Toxoplasma gondii | peptidylprolyl isomerase | 0.0097 | 0.9639 | 1 |
Plasmodium falciparum | pantothenate kinase 1, putative | 0.0082 | 0.7261 | 1 |
Trichomonas vaginalis | pantothenate kinase, putative | 0.0082 | 0.7261 | 0.6597 |
Loa Loa (eye worm) | Pin1-type peptidyl-prolyl cis-trans isomerase | 0.01 | 1 | 1 |
Echinococcus granulosus | expressed protein | 0.01 | 1 | 1 |
Trichomonas vaginalis | rotamase, putative | 0.0097 | 0.9639 | 0.9552 |
Giardia lamblia | Pantothenate kinase 4 | 0.0082 | 0.7261 | 0.5 |
Trichomonas vaginalis | rotamase, putative | 0.01 | 1 | 1 |
Schistosoma mansoni | rotamase | 0.01 | 1 | 1 |
Leishmania major | peptidyl-prolyl cis-trans isomerase/rotamase, putative,PPIase, putative | 0.0097 | 0.9639 | 1 |
Plasmodium vivax | pantothenate kinase, putative | 0.0082 | 0.7261 | 1 |
Toxoplasma gondii | fumble protein | 0.0082 | 0.7261 | 0.7533 |
Trichomonas vaginalis | conserved hypothetical protein | 0.01 | 1 | 1 |
Entamoeba histolytica | peptidyl-prolyl cis-trans isomerase, putative | 0.0097 | 0.9639 | 1 |
Trichomonas vaginalis | pantothenate kinase, putative | 0.0082 | 0.7261 | 0.6597 |
Echinococcus multilocularis | expressed protein | 0.01 | 1 | 1 |
Trichomonas vaginalis | pantothenate kinase, putative | 0.0082 | 0.7261 | 0.6597 |
Trypanosoma cruzi | peptidyl-prolyl cis-trans isomerase | 0.0097 | 0.9639 | 1 |
Trichomonas vaginalis | pantothenate kinase, putative | 0.0082 | 0.7261 | 0.6597 |
Onchocerca volvulus | Fumble homolog | 0.0082 | 0.7261 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.